Combination of the indoleamine 2,3-dioxygenase 1 inhibitor...

European Urology Supplements 2019 / 03 Vol. 18; Iss. 1

Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup

Moreno, V., Luke, J., Gelmon, K., Joshua, A.M., Varga, A.I., Desai, J., Markman, B., Gomez-Roca, C.A., De Braud, F., Patel, S.P., Carlino, M.S., Siu, L.L., Curigliano, G., Liu, Z., Ishii, Y., Wind-Rot
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
18
Language:
english
Journal:
European Urology Supplements
DOI:
10.1016/S1569-9056(19)31087-5
Date:
March, 2019
File:
PDF, 113 KB
english, 2019
Conversion to is in progress
Conversion to is failed